Silencing of miR-21 sensitizes CML CD34+ stem/progenitor cells to imatinib-induced apoptosis by blocking PI3K/AKT pathway

Leukemia Research

Volumn 39, Issue 10, 2015, Pages 1117-1124

  Wang, Wei Zhang ^a,b   Pu, Qiao Hong ^a,b   Lin, Xiang Hua ^c   Liu, Man Yu ^a   Wu, Li Rong ^a   Wu, Qing Qing ^a,b   Chen, Yong Heng ^a,b   Liao, Fen Fang ^a,b   Zhu, Jia Yong ^a   Jin, Xiao Bao ^a  

^a Guangdong Key Laboratory of Pharmaceutical Bioactive Substances   (China)

^b GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Apoptosis; CD34+ stem progenitor cells; CML; Imatinib; MiR 21

Indexed keywords

BIM PROTEIN; CD34 ANTIGEN; IMATINIB; MICRORNA 21; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 6; PROTEIN KINASE B; ANTINEOPLASTIC AGENT; MICRORNA; MIRN21 MICRORNA, HUMAN; PROTEIN KINASE INHIBITOR;

ADULT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; GENE SILENCING; GENE TARGETING; HUMAN; MALE; MIDDLE AGED; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STEM CELL; YOUNG ADULT; ANTAGONISTS AND INHIBITORS; CANCER STEM CELL; CHILD; DRUG EFFECTS; GENETIC TRANSFECTION; IMMUNOLOGY; INFANT; METABOLISM; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; APOPTOSIS; CHILD; FEMALE; GENE SILENCING; HUMANS; IMATINIB MESYLATE; INFANT; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MICRORNAS; MIDDLE AGED; NEOPLASTIC STEM CELLS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSFECTION; YOUNG ADULT;

EID: 84941316648     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2015.07.008     Document Type: Article

References (48)

1. Deininger M.W., Goldman J.M., Melo J.V. The molecular biology of chronic myeloid leukemia. Blood 2000, 96:3343-3356.
2. Michor F., Hughes T.P., Iwasa Y., Branford S., Shah N.P., Sawyers C.L., et al. Dynamics of chronic myeloid leukaemia. Nature 2005, 435:1267-1270.
3. Roeder I., Horn M., Glauche I., Hochhaus A., Mueller M.C., Loeffler M. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat. Med. 2006, 12:1181-1184.
4. Holtz M.S., Slovak M.L., Zhang F., Sawyers C.L., Forman S.J., Bhatia R. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 2002, 99:3792-3800.
5. Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl. J. Med. 2006, 355:2408-2417.
6. Corbin A.S., Agarwal A., Loriaux M., Cortes J., Deininger M.W., Druker B.J. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J. Clin. Invest. 2011, 121:396-409.
7. Bartel D.P. MicroRNAs genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
8. Ruan K., Fang X., Ouyang G. MicroRNAs novel regulators in the hallmarks of human cancer. Cancer Lett. 2009, 285:116-126.
9. Volinia S., Galasso M., Costinean S., Tagliavini L., Gamberoni G., Drusco A., et al. Reprogramming of miRNA networks in cancer and leukemia. Genome Res. 2010, 20:589-599.
10. Pan X., Wang Z.X., Wang R. MicroRNA-21: a novel therapeutic target in human cancer. Cancer Biol. Ther. 2010, 10:1224-1232.
11. Medina P.P., Nolde M., Slack F.J. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 2010, 467:86-90.
12. Sarkar F.H., Li Y., Wang Z., Kong D., Ali S. Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist. Updates 2010, 13:57-66.
13. Misawa A., Katayama R., Koike S., Tomida A., Watanabe T., Fujita N. AP-1-Dependent miR-21 expression contributes to chemoresistance in cancer stem cell-like SP cells. Oncol. Res. 2010, 19:23-33.
14. Chung W.M., Chang W.C., Chen L., Chang Y.Y., Shyr C.R., Hung Y.C., et al. MicroRNA-21 promotes the ovarian teratocarcinoma PA1 cell line by sustaining cancer stem/progenitor populations in vitro. Stem Cell Res. Ther. 2013, 4:88.
15. Han M., Liu M., Wang Y., Chen X., Xu J., Sun Y., et al. Antagonism of miR-21 reverses epithelial-mesenchymal transition and cancer stem cell phenotype through AKT/ERK1/2 inactivation by targeting PTEN. PLoS One 2012, 7:e39520.
16. Han M., Wang Y., Liu M., Bi X., Bao J., Zeng N., et al. MiR-21 regulates epithelial-mesenchymal transition phenotype and hypoxia-inducible factor-1alpha expression in third-sphere forming breast cancer stem cell-like cells. Cancer Sci. 2012, 103:1058-1064.
17. Li Y., Zhu X., Gu J., Dong D., Yao J., Lin C., et al. Anti-miR-21 oligonucleotide sensitizes leukemic K562 cells to arsenic trioxide by inducing apoptosis. Cancer Sci. 2010, 101:948-954.
18. Bai H., Xu R., Cao Z., Wei D., Wang C. Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line. FEBS Lett. 2011, 585:402-408.
19. Wang W.Z., Lin X.H., Pu Q.H., Liu M.Y., Li L., Wu L.R., et al. Targeting miR-21 sensitizes Ph+ ALL Sup-b15 cells to imatinib-induced apoptosis through upregulation of PTEN. Biochem. Biophys. Res. Commun. 2014, 454:423-428.
20. Yang C.H., Yue J., Fan M., Pfeffer L.M. IFN induces miR-21 through a signal transducer and activator of transcription 3-dependent pathway as a suppressive negative feedback on IFN-induced apoptosis. Cancer Res. 2010, 70:8108-8116.
21. Gwak H.S., Kim T.H., Jo G.H., Kim Y.J., Kwak H.J., Kim J.H., et al. Silencing of microRNA-21 confers radio-sensitivity through inhibition of the PI3K/AKT pathway and enhancing autophagy in malignant glioma cell lines. PLoS One 2012, 7:e47449.
22. Ma Y., Xia H., Liu Y., Li M. Silencing miR-21 sensitizes non-small cell lung cancer A549 cells to ionizing radiation through inhibition of PI3K/Akt. Biomed. Res. Int. 2014, 2014:617868.
23. Guan H., Song L., Cai J., Huang Y., Wu J., Yuan J., et al. Sphingosine kinase 1 regulates the Akt/FOXO3a/Bim pathway and contributes to apoptosis resistance in glioma cells. PLoS One 2011, 6:e19946.
24. Brunet A., Bonni A., Zigmond M.J., Lin M.Z., Juo P., Hu L.S., et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999, 96:857-868.
25. Chandramohan V., Jeay S., Pianetti S., Sonenshein G.E. Reciprocal control of Forkhead box O 3a and c-Myc via the phosphatidylinositol 3-kinase pathway coordinately regulates p27Kip1 levels. J. Immunol. 2004, 172:5522-5527.
26. Hurtz C., Hatzi K., Cerchietti L., Braig M., Park E., Kim Y.M., et al. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J. Exp. Med. 2011, 208:2163-2174.
27. King B., Trimarchi T., Reavie L., Xu L., Mullenders J., Ntziachristos P., et al. The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell 2013, 153:1552-1566.
28. Quintas-Cardama A., Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009, 113:1619-1630.
29. Saglio G., Kim D.W., Issaragrisil S., le Coutre P., Etienne G., Lobo C., et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl. J. Med. 2010, 362:2251-2259.
30. Kantarjian H., Shah N.P., Hochhaus A., Cortes J., Shah S., Ayala M., et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl. J. Med. 2010, 362:2260-2270.
31. Chu S., McDonald T., Lin A., Chakraborty S., Huang Q., Snyder D.S., et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood 2011, 118:5565-5572.
32. Li L., Wang L., Wang Z., Ho Y., McDonald T., Holyoake T.L., et al. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 2012, 21:266-281.
33. Takeishi S., Matsumoto A., Onoyama I., Naka K., Hirao A., Nakayama K.I. Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence. Cancer Cell 2013, 23:347-361.
34. Niu Z., Goodyear S.M., Rao S., Wu X., Tobias J.W., Avarbock M.R., et al. MicroRNA-21 regulates the self-renewal of mouse spermatogonial stem cells. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:12740-12745.
35. Lu T.X., Lim E.J., Itskovich S., Besse J.A., Plassard A.J., Mingler M.K., et al. Targeted ablation of miR-21 decreases murine eosinophil progenitor cell growth. PLoS One 2013, 8:e59397.
36. Polak R., Buitenhuis M. The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia. Blood 2012, 119:911-923.
37. Airiau K., Mahon F.X., Josselin M., Jeanneteau M., Belloc F. PI3K/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor. Cell Death Dis. 2013, 4:e827.
38. Buitenhuis M., Verhagen L.P., van Deutekom H.W., Castor A., Verploegen S., Koenderman L., et al. Protein kinase B (c-akt) regulates hematopoietic lineage choice decisions during myelopoiesis. Blood 2008, 111:112-121.
39. Gunther R., Abbas H.K., Mirocha C.J. Acute pathological effects on rats of orally administered wortmannin-containing preparations and purified wortmannin from Fusarium oxysporum. Food Chem. Toxicol. 1989, 27:173-179.
40. Zeng Z., Samudio I.J., Zhang W., Estrov Z., Pelicano H., Harris D., et al. Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP 372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Cancer Res. 2006, 66:3737-3746.
41. Meng F., Henson R., Wehbe-Janek H., Ghoshal K., Jacob S.T., Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133:647-658.
42. Wang P., Zou F., Zhang X., Li H., Dulak A., Tomko R.J., et al. microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. Cancer Res. 2009, 69:8157-8165.
43. Bourguignon L.Y., Spevak C.C., Wong G., Xia W., Gilad E. Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the Production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J. Biol. Chem. 2009, 284:26533-26546.
44. Connolly E.C., Van Doorslaer K., Rogler L.E., Rogler C.E. Overexpression of miR-21 promotes an in vitro metastatic phenotype by targeting the tumor suppressor RHOB. Mol. Cancer Res. 2010, 8:691-700.
45. Valeri N., Gasparini P., Braconi C., Paone A., Lovat F., Fabbri M., et al. MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc. Natl. Acad. Sci. U. S. A. 2010, 107:21098-21103.
46. Luo H., Yang Y., Duan J., Wu P., Jiang Q., Xu C. PTEN-regulated AKT/FoxO3a/Bim signaling contributes to reactive oxygen species-mediated apoptosis in selenite-treated colorectal cancer cells. Cell Death Dis. 2013, 4:e481.
47. Wang W.Q., Zhang H., Wang H.B., Sun Y.G., Peng Z.H., Zhou G., et al. Programmed cell death 4 (PDCD4) enhances the sensitivity of gastric cancer cells to TRAIL-induced apoptosis by inhibiting the PI3K/Akt signaling pathway. Mol. Diagn. Ther. 2010, 14:155-161.
48. Frankel L.B., Christoffersen N.R., Jacobsen A., Lindow M., Krogh A., Lund A.H. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J. Biol. Chem. 2008, 283:1026-1033.